Want to see TSE:IZO full AI Analyst Report?
IZO Stock Chart & Stats
C$0.25
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.25
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.49
Previous CloseN/A
Volume4.00K
Average Volume (3M)43.33K
Market Cap
C$17.25M
Enterprise ValueC$21.05M
Total Cash (Recent Filing)C$364.08K
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding68,984,680
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dedicated Product FocusIzotropic's singular focus on a dedicated breast CT system represents a structural product advantage versus multi-modality competitors. If clinically validated and commercialized, the device could offer durable differentiation in workflow and diagnostic accuracy for breast imaging, addressing a large, stable screening market and creating a defensible niche.
Moderating Cash BurnA marked reduction in cash burn versus prior years signals improving operating efficiency or progress in development stages. This moderation lowers immediate financing pressure, extending runway and giving management more time to reach milestones that can convert development spending into potential revenue or strategic funding alternatives.
Progress Toward Smaller LossesA consistent decline in net losses over multiple years reflects structural cost control or milestone-driven de-risking of development programs. Sustained narrowing of losses improves the company's ability to plan longer-term, reduces frequency of dilutive financing events, and strengthens the case for continued investor and partner support.
Bears Say
No RevenueAbsence of any reported revenue means the product has not yet validated market demand, so operational progress remains not monetized. This structural gap forces reliance on external capital to fund operations and creates execution risk: commercialization delays or clinical setbacks would materially extend funding needs and strategic uncertainty.
Negative Equity & Thin Asset BaseNegative shareholders' equity and high debt relative to tiny assets indicate accumulated losses and weakened solvency. This structural balance-sheet weakness raises refinancing and covenant risk, limits strategic flexibility, and could increase cost of capital or force unfavorable financing if additional funds are required before revenue generation.
Persistent Negative Cash FlowOngoing negative operating and free cash flow implies the company must continue to access external capital or restructure spending. Over a multi-month horizon, persistent cash burn without revenue creates dilution or leverage risk and constrains investment in commercialization or clinical programs necessary to realize the product's long-term potential.
Izotropic News
IZO FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is C$17.25M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Aug 21, 2026 which is in 18 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 68,984,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in TSE:IZO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imaging platform, both specifically designed to enable earlier detection and more accurate diagnosis of the disease. Established in 2016, the company maintains its corporate base in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―